George Wilding
University of Wisconsin-Madison
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by George Wilding.
Cancer | 1993
Bruce J. Roth; Patrick J. Loehrer; Beow Yong Yeap; George Wilding; Basil Kasimis; David McLeod
Background. Recent clinical trials have documented activity for combinations of chemotherapeutic agents that target the microtubular apparatus in patients with hormone‐refractory prostate cancer. Taxol has a novel antimicrotubular mechanism, acting by stabilizing polymerized tubulin.
Cancer | 2004
Robert Dreicer; Judith Manola; Bruce J. Roth; William A. See; Steven Kuross; Martin J. Edelman; Gary R. Hudes; George Wilding
The regimens of carboplatin plus paclitaxel (CP) and methotrexate, vinblastine, doxorubicin, and cisplatin (M‐VAC) were compared in patients with advanced urothelial carcinoma.
Cancer | 2002
David J. Vaughn; Judith Manola; Robert Dreicer; William See; Ralph Levitt; George Wilding
Chemotherapy options for the patients with advanced urothelial carcinoma and renal dysfunction are limited. The authors performed a Phase II trial of paclitaxel plus carboplatin in patients with advanced carcinoma of the urothelium and renal dysfunction.
Cancer | 2003
Robert Dreicer; Judith Manola; Daniel J. Schneider; John F. Schwerkoske; Christopher S. George; Bruce J. Roth; George Wilding
Gemcitabine and docetaxel are active agents in advanced urothelial carcinoma. A Phase II trial of this combination was performed to determine the activity and toxicity of these agents in a multiinstitutional setting in patients previously treated with one prior chemotherapy regimen.
Cancer | 2006
George Wilding; Patrick Soulié; Donald Trump; Ashis Das-Gupta; Eric Small
Gefitinib, which is an orally active epidermal growth factor receptor tyrosine kinase inhibitor, has demonstrated activity against hormone‐refractory prostate cancer (HRPC) in preclinical studies. In this pilot Phase I trial, the authors evaluated the tolerability, efficacy, and pharmacokinetics of gefitinib combined with estramustine and docetaxel in patients with HRPC.
Cancer | 2004
Tim A. Ahles; James E. Herndon; Eric J. Small; Nicholas J. Vogelzang; Alice B. Kornblith; Mark J. Ratain; Walter M. Stadler; David Palchak; M. Ernest Marshall; George Wilding; Daniel Petrylak; Jimmie C. Holland
Research has suggested that men with hormone‐refractory prostate carcinoma have a lower quality of life (QOL) compared with men who have hormone‐sensitive prostate carcinoma and that quality of life (QOL) steadily declines over the last year of life for men with prostate carcinoma. The primary purpose of the current study was to evaluate whether there was evidence of palliative effects associated with suramin at any of the three doses administered in the original clinical trial.
Cancer | 2005
Janice P. Dutcher; Larry F. Leon; Judith Manola; David M. Friedland; Bruce Roth; George Wilding
The current study evaluated the response rate and 6‐month time to disease progression of the antiangiogenesis agent carboxyamidotriazole (CAI) in patients with metastatic renal cell carcinoma (RCC).
Cancer Investigation | 2003
Roland T. Skeel; Jie Huang; Judith Manola; George Wilding; Robert Dreicer; Paul Walker; Franco Muggia; E. David Crawford; Janice P. Dutcher; Patrick J. Loehrer
Purpose. Combined biological therapy with 13-cis-retinoic acid (13-cRA) and interferon alpha-2a (IFN α-2a) was reported to be highly effective in squamous cell carcinoma of the cervix and skin. Squamous cell carcinoma of the penis is rare in the United States, accounting for less than1/2% of all male malignancies. Because of the association of infection with human papillomavirus with both carcinomas of the cervix and penis and their shared squamous cell histology, we carried out a phase II study of 13-cRA and IFN α-2a in carcinoma of the penis. Materials and Methods. Eighteen ambulatory patients with surgically unresectable, recurrent, and/or metastatic squamous cell carcinoma of the penis were treated with IFN α-2a, 3 MU/day administered subcutaneously and 13-cRA, l mg/kg orally daily for at least eight weeks, unless intolerable toxicity occurred. Results. One patient was ineligible; one patient withdrew prior to treatment. Among the 16 eligible, treated patients, there was one complete response. Fourteen patients had progressive disease as their only treatment effect. Two patients were unevaluable for tumor response because they had no follow-up tumor measurements. No unexpected treatment-related toxicities were found on study. The only common form of grade 3 toxicity was hypertriglyceridemia found in eight of the 17 patients (47%). No toxicities above grade 3 were observed. Conclusion. In contrast to its benefit in squamous cell carcinomas of the cervix and skin, the combination of 13-cRA and IFN α-2a has low efficacy in advanced carcinoma of the penis.
Cancer | 2000
Kirsten M. Hotton; Masoud Khorsand; Jacquelyn A. Hank; Mark Albertini; Kyung Mann Kim; George Wilding; M. Shahriar Salamat; B A Marilyn Larson; Paul M. Sondel; Joan H. Schiller
Interleukin‐2 (IL‐2) and granulocyte‐macrophage−colony stimulating factor (GM‐CSF) are cytokines with nonoverlapping pleiotropic effects. In a prior Phase Ib study, this combination of agents exhibited antitumor effects in the lungs of four of eight patients with renal cell carcinoma and pulmonary metastases. We conducted this Phase Ib/II trial to determine the response rate of renal cell carcinoma patients with pulmonary metastases treated with continuous infusion IL‐2 plus GM‐CSF.
Cancer | 2003
Robert Dreicer; Bruce Roth; George Wilding
Advanced transitional cell carcinoma of the urothelium is an aggressive malignancy characterized by a median survival period of less than 1 year. Although this disease is moderately chemotherapy‐sensitive, to the authors knowledge the impact of therapy reported to date on survival has been minimal. The authors presented an overview of the results from a series of clinical trials conducted over a 25‐year period under the auspices of the Eastern Cooperative Oncology Group. They reviewed a series of antineoplastic agents identified by these studies with activity in advanced urothelial cancer and discussed current and future investigational goals and directions. Cancer 2003;97(8 Suppl):2109–14.